Bicyclic Heterocyclic Compounds Targeting Huntington's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no current small molecule therapies targeting the underlying cause of Huntington's disease, leaving a high unmet need for medications that can treat or ameliorate the condition.
Innovation Solution
Development of substituted bicyclic heterocyclic and heteroaryl compounds, such as those described by Formula (I), which can be administered to subjects to treat or ameliorate Huntington's disease by targeting the underlying cause.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule therapies are developed to target the underlying cause of Huntington's disease, then therapeutic efficacy is improved, but currently no such therapies exist leaving an unmet need
Solution Approach 1:
The patent segments the therapeutic approach by developing distinct small molecule compounds with specific heterocyclic structures that can be administered independently or in combination, allowing targeted intervention at the molecular level while providing multiple discrete treatment options for Huntington's disease
Solution Approach 2:
The small molecule compounds act as intermediary substances that mediate between the administered drug and the underlying cause of Huntington's disease, specifically targeting the mutant huntingtin protein or its effects at the molecular level to produce therapeutic effects
2Reliability
If substituted bicyclic heterocyclic and heteroaryl compounds are administered to treat Huntington's disease, then the underlying cause is targeted, but further clinical validation is needed
Solution Approach 1:
The patent performs preliminary actions by conducting extensive in vitro and in vivo studies, structure-activity relationship analyses, and preclinical evaluations to validate the therapeutic potential of the compounds before clinical trials, thereby reducing the time and uncertainty associated with later-stage validation
Data Source
AI summary
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.